ACE and heart failure: Santema et al. investigated sex differences in the optimal dose of ACE inhibitors or ARBs and beta blockers in patients with heart failure with reduced ejection fraction (HFrEF) and showed that women had 30% lower risk at only 50% of the recommended doses, with no further decrease in risk at higher dose levels [42].